NCT07171359 TMS to Improve Recovery Outcomes Among Patients With Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD)
| NCT ID | NCT07171359 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington State University |
| Condition | Alcohol Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2027-06-01 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2027-06-01 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to explore the potential of Transcranial Magnetic Stimulation (TMS), particularly Theta Burst Stimulation (TBS), as an adjunctive treatment to enhance recovery outcomes (consumption and craving; withdrawal symptoms; mental, physical, sleep, and cognitive health; engagement with therapy, etc.) in individuals with Opioid Use Disorder (OUD) and individuals with Alcohol Use Disorder (AUD). This project will be completed in partnership with Another Chance Rehab (Portland): Portland's top addiction treatment program offering evidence-based treatment programs for a range of substance use disorders. Another Chance Rehab will serve as the project site for this work.
Eligibility Criteria
Inclusion Criteria: * 18+ years old * Enrolled in the Intensive Outpatient Program at Another Chance Drug \& Alcohol Rehab Center of Portland, Portland, OR. * Diagnosed with Opioid Use Disorder * Diagnosed with Alcohol Use Disorder Exclusion Criteria: * Children \<18 years old * Pregnant * Non-English speaking * Currently taking prescription benzodiazepines or anti-convulsive medications * In active alcohol or opioid withdrawal * History of seizure disorder diagnosis * History of Schizophrenia, Bipolar Disorder, Mania
Contact & Investigator
Matthew E Layton, MD, PhD
PRINCIPAL INVESTIGATOR
Washington State University
Frequently Asked Questions
Who can join the NCT07171359 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alcohol Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07171359 currently recruiting?
Yes, NCT07171359 is actively recruiting participants. Contact the research team at layton@wsu.edu for enrollment information.
Where is the NCT07171359 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT07171359 clinical trial?
NCT07171359 is sponsored by Washington State University. The principal investigator is Matthew E Layton, MD, PhD at Washington State University. The trial plans to enroll 60 participants.